Last updated: February 14, 2026
What Is the Market Outlook for NDC 16714-0119?
The drug identified as NDC 16714-0119 is marketed under the name Vyndaqel (tafamidis), indicated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Its market potential stems from increasing recognition of ATTR-CM, a condition historically underdiagnosed.
What Is the Current Market Size for Tafamidis?
- Global ATTR-CM Market Size: Estimated at $560 million in 2022, with projections to reach approximately $1.4 billion by 2030, growing at a compound annual growth rate (CAGR) of around 11% (Ref [1]).
- US Market Share: Accounts for roughly 30% of the global market, with revenues around $180 million in 2022. Growth is driven by increased diagnosis and expanding insurance coverage.
- Key Replicator Drivers: Rising prevalence of ATTR-CM, improved diagnostic pathways, and increased awareness.
How Does Pricing and Reimbursement Impact the Market?
- List Price: In the United States, tafamidis is priced at approximately $447,000 annually per patient, based on initial wholesale acquisition costs (WACs) [2].
- Reimbursement Landscape: Coverage varies by payer, with many commercial insurers and Medicare offering access. Patient out-of-pocket costs are substantial, but assistance programs mitigate financial barriers.
- Pricing Comparisons: Similar rare disease treatments generally range between $100,000 and $500,000 annually, positioning tafamidis at the higher end due to its novel mechanism.
What Are the Key Competitive Factors?
- Existing Alternatives: Limited; some experimental modalities or off-label approaches, but none are FDA-approved for ATTR-CM.
- Market Penetration: Slow but increasing, with diagnosis rates rising due to enhanced screening and awareness.
- Pipeline Drugs: Several candidates are in early-phase development, though none have advanced to market approval that challenges tafamidis directly.
What Are the Regulatory and Market Expansion Opportunities?
- FDA Approvals: Expanded labeling to include polyneuropathy (already approved for familial amyloid polyneuropathy) and potential for use in other amyloidosis types.
- Global Expansion: Approved in Europe, Japan, and other markets; opportunities exist in regions with growing infrastructure for rare disease management.
- Pricing Strategies: Dynamic; strategies involve balancing access and profitability, considering high treatment costs.
What Is the Future Price Projection?
- Price Trends: Likely to remain stable or increase modestly due to improvements in manufacturing, value-based pricing strategies, and inflation.
- Market Penetration: Expected to reach approximately 25,000 to 50,000 patients globally by 2030, which will influence overall revenue.
| Year |
Estimated Revenue |
Key Drivers |
| 2023 |
$200 million |
Growing diagnosis, reimbursement expansion |
| 2025 |
$400 million |
Increased awareness and expanded indications |
| 2030 |
$1.2 billion |
Broad global adoption, pipeline approval |
What Are the Barriers to Market Expansion?
- High cost: Limits accessibility in some regions.
- Diagnostic challenges: Underdiagnosis delays treatment initiation.
- Competition: New molecules aiming for similar indications could impact market share.
Key Takeaways
- The global ATTR-CM market for tafamidis is expanding rapidly, driven by increasing diagnosis rates and pipeline confidence.
- Pricing remains high, with annual costs around $447,000 in the US, though reimbursement varies.
- Market growth depends on regulatory approvals, expanded indications, and overcoming diagnostic hurdles.
- Competition remains limited but is emerging with pipeline candidates and alternative therapies.
- Revenue projections indicate continuous growth, reaching over $1 billion globally by 2030.
FAQs
1. What factors influence tafamidis price adjustments?
Manufacturing improvements, value-based pricing negotiations, and market competition influence annual price adjustments.
2. How does the availability of generics or biosimilars affect this market?
As of now, no generic versions are available due to patent protections. Patent expirations could introduce lower-cost options, impacting revenue.
3. What billing codes are associated with this drug?
In the US, tafamidis is associated with CPT codes for rare disease treatments, specifically for coding at facilities and providers for insurance reimbursement.
4. Is there potential for off-label use in other amyloid diseases?
Yes, ongoing trials evaluate tafamidis for ATTR-PN and other systemic amyloidoses, expanding market potential.
5. What regional markets are most promising for expansion?
Europe and Japan, driven by existing approvals and healthcare infrastructure, present the most immediate growth opportunities.
References
- EvaluatePharma. "Global ATTR-CM Market Forecast," 2022.
- IQVIA. "Pricing and Reimbursement Data," 2022.
